|
Retlirafusp alfa Clinical Trials
2 actively recruiting trials
Also known as: shr-1701
Pipeline
Phase 2: 1
Top Sponsors
- The First Affiliated Hospital with Nanjing Medical University1
- Nanjing Tianyinshan Hospital1
Indications
- Cancer2
- Liver Disease1
- Hepatocellular Carcinoma (HCC)1
- Intrahepatic Cholangiocarcinoma (ICC)1
- Liver Cancer1
Other2 trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.